SETTING: Recently, Mycobacterium tuberculosis isolates have been described that test phenotypically susceptible to rifampicin (RMP) yet harbour genotypic rpoB mutations. OBJECTIVE: 1) To investigate the impact of such mutations on clinical outcomes among RMP-susceptible isolates, and 2) to determine the prevalence of rpoB mutations among isoniazid (INH) monoresistant isolates at our laboratory and to describe the association between the presence of these mutations and clinical outcomes. METHODS: M. tuberculosis isolates were screened for mutations in the rpoB gene using the Cepheid Gene-Xpert® MTB/RIF assay. Clinical correlation was made by reviewing patient case notes. RESULTS: Isolates from 94 patients were found to have INH-resistant, RMP-susceptible profiles. Clinical information was available for 52 patients, including three whose isolates had rpoB mutations. All three of these patients had treatment failures, compared to two of 49 patients whose isolates did not have rpoB mutations (P = 0.0005). DISCUSSION: We demonstrate a significant association between the presence of rpoB gene mutations that are not detected at the current RMP critical concentration and treatment failure. We suggest that a review of the current RMP critical concentration is warranted to ensure that RMP is not used inappropriately for the treatment of phenotypically occult multidrug-resistant tuberculosis.
SETTING: Recently, Mycobacterium tuberculosis isolates have been described that test phenotypically susceptible to rifampicin (RMP) yet harbour genotypic rpoB mutations. OBJECTIVE: 1) To investigate the impact of such mutations on clinical outcomes among RMP-susceptible isolates, and 2) to determine the prevalence of rpoB mutations among isoniazid (INH) monoresistant isolates at our laboratory and to describe the association between the presence of these mutations and clinical outcomes. METHODS:M. tuberculosis isolates were screened for mutations in the rpoB gene using the Cepheid Gene-Xpert® MTB/RIF assay. Clinical correlation was made by reviewing patient case notes. RESULTS: Isolates from 94 patients were found to have INH-resistant, RMP-susceptible profiles. Clinical information was available for 52 patients, including three whose isolates had rpoB mutations. All three of these patients had treatment failures, compared to two of 49 patients whose isolates did not have rpoB mutations (P = 0.0005). DISCUSSION: We demonstrate a significant association between the presence of rpoB gene mutations that are not detected at the current RMP critical concentration and treatment failure. We suggest that a review of the current RMP critical concentration is warranted to ensure that RMP is not used inappropriately for the treatment of phenotypically occult multidrug-resistant tuberculosis.
Authors: Sophia B Georghiou; Marva Seifert; Donald G Catanzaro; Richard S Garfein; Timothy C Rodwell Journal: J Clin Microbiol Date: 2017-04-12 Impact factor: 5.948
Authors: Soumitesh Chakravorty; Harsheel Kothari; Bola Aladegbami; Eun Jin Cho; Jong Seok Lee; Sandy S Roh; Hyunchul Kim; Hyungkyung Kwak; Eun Gae Lee; Soo Hee Hwang; Padmapriya P Banada; Hassan Safi; Laura E Via; Sang-Nae Cho; Clifton E Barry; David Alland Journal: J Clin Microbiol Date: 2012-04-25 Impact factor: 5.948
Authors: Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong Journal: J Clin Microbiol Date: 2013-06-12 Impact factor: 5.948
Authors: N N Abanda; J Y Djieugoué; V S Khadka; E W Pefura-Yone; W F Mbacham; G Vernet; V M Penlap; Y Deng; S I Eyangoh; D W Taylor; R G F Leke Journal: Clin Microbiol Infect Date: 2017-12-05 Impact factor: 8.067
Authors: Karen R Steingart; Hojoon Sohn; Ian Schiller; Lorie A Kloda; Catharina C Boehme; Madhukar Pai; Nandini Dendukuri Journal: Cochrane Database Syst Rev Date: 2013-01-31